Naltrexone News and Research

RSS

Symptoms of alcoholism affect prescription drug adherence to treat disease

Symptoms of alcoholism make it more difficult for some people to regularly take the prescription drug naltrexone, which could help treat their disease, a researcher at Oregon State University has found.

8 Feb 2018

Scientists develop potential new antidepressant with unique mechanism of action

A potential new antidepressant and antianxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.

6 Nov 2017

Study identifies potential biomarker for onset, progression of MS

An article published in Experimental Biology and Medicine identifies Opioid Growth Factor (OGF) as a novel biomarker for the onset and progression of multiple sclerosis (MS).

27 Sep 2017

Research shows link between brain's immune system and desire to drink alcohol

Researchers from the University of Adelaide have found a new link between the brain's immune system and the desire to drink alcohol in the evening.

15 Sep 2017

Study highlights critical gap in addiction treatment for young people with OUD

Only one in four young adults and teens with opioid use disorder are receiving potentially life-saving medications for addiction treatment, according to a new Boston Medical Center study published online in JAMA Pediatrics.

19 Jun 2017

People in recovery worry GOP Medicaid cuts would put treatment out of reach

Republicans in both the House and the Senate are considering big cuts to Medicaid. But those cuts endanger addiction treatment, which many people receive through the government health insurance program.

14 Jun 2017

Medical responses to opioid addiction vary by state, analysis finds

Location, location, location. That mantra may apply even when it comes to how opioid addiction is treated.

12 Jun 2017

New study finds opioid dependence affects perception of cute images of babies

A new pilot study has found that opioid dependence - which includes dependence on drugs such as heroin - affects how 'cute' we perceive images of children to be.

19 Sep 2016

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

27 May 2016

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

In a multicenter, randomized clinical trial, ex-prisoners who received six monthly injections of naltrexone--a long-acting medication that blocks opioid receptors in the brain--were significantly less likely to resume opioid use than those who received counseling and referrals to community treatment centers without naltrexone.

31 Mar 2016

Opioids could be dangerous, deadly at high doses

Most people know that heroin is a dangerous drug, but its cousins, the legal, pharmaceutical opioids, such as codeine or hydrocodone, must be safe, right?Not so fast.Opioids—which include the illegal drug heroin as well as prescription medications, including hydrocodone (such as Vicodin), oxycodone (such as OxyContin and Percocet), morphine and codeine—can be dangerous, even deadly, at high doses.

31 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration.

31 Dec 2015

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development for the treatment of opioid addiction.

5 Nov 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments.

25 Sep 2015

Drug addiction expert uncovers molecular mechanisms that contribute to addiction resistance

Growing up in West Virginia, Jill Turner saw firsthand the kind of havoc that drug addiction can wreak. "I had a lot of friends who had very promising lives and promising careers ahead of them," the assistant professor in the South Carolina College of Pharmacy says, "but they ended up either overdosing or going to jail for drug-related stuff. It's one of the reasons I went into drug addiction research."

22 Jul 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine.

19 May 2015